Outcomes of Radiofrequency Ablation for Colorectal Liver Metastases
Main Article Content
Abstract
This study aimed to describe the imaging characteristics and evaluate the early outcomes of radiofrequency ablation (RFA) in the treatment of colorectal liver metastases at Hanoi Medical University Hospital. A descriptive observational study was conducted on 25 patients with 38 metastatic liver lesions between January 2024 and April 2026. Treatment response was assessed using magnetic resonance imaging (MRI) or computed tomography (CT) according to the modified Response Evaluation Criteria in Solid Tumors (mRECIST).
The mean patient age was 56.7 ± 12.7 years, with a nearly equal male-to-female ratio. Most lesions were located in hepatic segment VI (39.5%). The mean tumor size was 17.8 ± 6.0 mm, and the majority of patients presented with a solitary liver lesion (64%).
According to the mRECIST criteria, the complete local response rate at 3 months was 84.2%. Lesions measuring ≤20 mm tended to achieve a higher complete response rate than lesions measuring >20–30 mm (91.7% vs. 71.4%, respectively; p = 0.17). Complications were predominantly mild and transient, with no major procedure-related complications according to the CIRSE classification.
Conclusion
Radiofrequency ablation is a safe and minimally invasive treatment modality with favorable early outcomes for local tumor control in colorectal liver metastases.
Keywords
colorectal liver metastases; radiofrequency ablation; local tumor control.
Keywords
colorectal liver metastases, radiofrequency ablation, early local treatment response.
Article Details
References
Cancers in 185 Countries,” CA Cancer J Clin, vol. 71, no. 3, pp. 209–249, May 2021, doi: 10.3322/caac.21660.
2. J. Engstrand, H. Nilsson, C. Stromberg, E. Jonas, and J. Freedman, “Colorectal cancer liver metastases - a
population-based study on incidence, management and survival,” BMC Cancer, vol. 18, no. 1, p. 78, Jan 15 2018,
doi: 10.1186/s12885-017-3925-x.
3. R. Adam et al., “The oncosurgery approach to managing liver metastases from colorectal cancer: a multidisciplinary
international consensus,” Oncologist, vol. 17, no. 10, pp. 1225–39, 2012, doi: 10.1634/theoncologist.2012-0121.
4. E. Van Cutsem et al., “ESMO consensus guidelines for the management of patients with metastatic colorectal
cancer,” Ann Oncol, vol. 27, no. 8, pp. 1386–422, Aug 2016, doi: 10.1093/annonc/mdw235.
5. A. Stang, K. J. Oldhafer, H. Weilert, H. Keles, and M. Donati, “Selection criteria for radiofrequency ablation for
colorectal liver metastases in the era of effective systemic therapy: a clinical score based proposal,” BMC Cancer,
vol. 14, p. 500, Jul 9 2014, doi: 10.1186/1471-2407-14-500.
6. A. Hamada et al., “Radiofrequency ablation for colorectal liver metastases: prognostic factors in non-surgical
candidates,” Jpn J Radiol, vol. 30, no. 7, pp. 567–74, Aug 2012, doi: 10.1007/s11604-012-0089-0.
7. C. Z. Wang, G. X. Yan, H. Xin, and Z. Y. Liu, “Oncological outcomes and predictors of radiofrequency ablation of
colorectal cancer liver metastases,” World J Gastrointest Oncol, vol. 12, no. 9, pp. 1044–1055, Sep 15 2020, doi:
10.4251/wjgo.v12.i9.1044.
8. K. A. Paschos and N. Bird, “Current diagnostic and therapeutic approaches for colorectal cancer liver metastasis,”
Hippokratia, vol. 12, no. 3, pp. 132–8, Jul 2008. [Online]. Available: https://www.ncbi.nlm.nih.gov/pubmed/18923747.
9. O. Akhan, S. Akcalar, E. Unal, Y. Metin, T. Ciftci, and D. Akinci, “Radiofrequency Ablation for Colorectal Cancer
Liver Metastases: Outcomes and Prognostic Factors Associated with Survival,” Turk J Gastroenterol, vol. 34, no. 6, pp. 645–651, Jun 2023, doi: 10.5152/tjg.2023.22088.
10. M. Bruegel et al., “Diagnosis of hepatic metastasis: comparison of respiration-triggered diffusion-weighted echoplanar MRI and five t2-weighted turbo spin-echo sequences,” AJR Am J Roentgenol, vol. 191, no. 5, pp. 1421–9, Nov 2008, doi: 10.2214/AJR.07.3279.
11. M. C. Niekel, S. Bipat, and J. Stoker, “Diagnostic imaging of colorectal liver metastases with CT, MR imaging,
FDG PET, and/or FDG PET/CT: a meta-analysis of prospective studies including patients who have not previously
undergone treatment,” Radiology, vol. 257, no. 3, pp. 674–84, Dec 2010, doi: 10.1148/radiol.10100729.
12. K. Sivesgaard et al., “Diagnostic accuracy of CE-CT, MRI and FDG PET/CT for detecting colorectal cancer liver
metastases in patients considered eligible for hepatic resection and/or local ablation,” Eur Radiol, vol. 28, no. 11,
pp. 4735–4747, Nov 2018, doi: 10.1007/s00330-018-5469-0.
13. X. Wang et al., “Margin size is an independent predictor of local tumor progression after ablation of colon cancer
liver metastases,” Cardiovasc Intervent Radiol, vol. 36, no. 1, pp. 166–75, Feb 2013, doi: 10.1007/s00270-012- 0377-1.
14. A. R. Gillams and W. R. Lees, “Five-year survival in 309 patients with colorectal liver metastases treated with
radiofrequency ablation,” Eur Radiol, vol. 19, no. 5, pp. 1206–13, May 2009, doi: 10.1007/s00330-008-1258-5.
15. C. Correa-Gallego et al., “A retrospective comparison of microwave ablation vs. radiofrequency ablation for
colorectal cancer hepatic metastases,” Ann Surg Oncol, vol. 21, no. 13, pp. 4278–83, Dec 2014, doi: 10.1245/s10434-014-3817-0.